Finding assets, creating spin-outs, commercialising cancer therapies
Need for improvement in oncology drug development success rates
Despite progress in improving clinical outcomes for a range of different cancers, a persistently high failure rate in late-stage clinical development exists in this field. By adopting strict criteria early in the development process and focusing on patient sub-group approaches, Cumulus seeks to identify and prioritise those assets and programs that hold the highest potential for clinical success. This has the dual effect of reducing both the late-stage clinical failure rates as well as the high sunk costs that accompany this reality.
Driving oncology innovation
Cumulus Oncology connects the dots between oncology research, drug discovery, development, commercialisation and value creation to accelerate drug development programs, create new companies, and co-develop or license attractive assets/targets in oncology.
Finding
assets
Creating
spin-outs
Commercialising
cancer therapies
Cumulus works with asset holders from various backgrounds (both academic and commercial) to ensure the best science is moved forward effectively. We use a ‘one team – multiple companies/projects’ approach, enabling through a highly efficient deployment of resources and capital.
Who we are
We bring together scientific experts, entrepreneurs, investment specialists, leading drug discovery, drug development and commercialisation professionals all committed to one common goal: to accelerate oncology innovation into world changing impact. Cumulus puts its expertise and entrepreneurship at the heart of biotech company creation to drive patient benefit and shareholder value.
We are hiring
Want to be part of a mission-led company in oncology drug development?
